Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022 Confirmatory patient study for AVT05, a proposed biosimilar for Simponi ® and Simponi Aria ® (golimumab) initiated, marking the fifth internally developed portfolio candidate

REYKJAVIK, Iceland, May 17, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley Annual Sustainable Finance Summit on May 22,

Alvotech’s global workforce is now evenly split between females and males, and the unexplained gender pay gap has been reduced to 1.6% from 5.2% in December 2020 Alvotech’s Equality Policy, which is based on Icelandic law, has been implemented for the workforce globally REYKJAVIK, Iceland, May 15,

Polifarma will commercialize AVT06, a proposed biosimilar to Eylea ® (aflibercept), in Turkey REYKJAVIK, Iceland, May 10, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today

The Annual General Meeting of Alvotech S.A. will be held on Tuesday 6 June 2023, at 09.00 a.m. CEST at the premises of Arendt & Medernach S.A. at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg. Reference is made to the attached document with regard to the final agenda.

The clinical study will compare AVT05 and Simponi ® in patients with moderate to severe rheumatoid arthritis REYKJAVIK, Iceland, May 04, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients

REYKJAVIK, Iceland, May 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2023,

REYKJAVIK, Iceland, April 19, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to the company’s Quality unit.

REYKJAVIK, Iceland, April 14, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO ), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response